CAD-1005 (formerly VLX-1005)

June 24, 2026: Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) announced that late-breaking clinical data from its Phase 2 study of CAD-1005 (formerly VLX-1005), a first-in-class 12-lipoxygenase (12-LOX) inhibitor for heparin-induced thrombocytopenia (HIT), have been accepted for an oral late-breakthrough presentation at the 34th International Society on Thrombosis and Haemostasis (ISTH) Congress in Paris (July 11–15, 2026). The abstract, “12-lipoxygenase inhibition with VLX-1005 in heparin-induced thrombocytopenia,” was selected for the “Late-Breakthrough Abstracts I: Clinical Trials and Innovation in Thrombosis” session.

The company states the data come from the first-ever randomized, blinded, placebo-controlled trial in HIT and positions CAD-1005 as “Phase-3 ready.” The presentation is scheduled for July 12, 2026 (11:15 AM–12:00 PM CEST).

Regulatory status noted: CAD-1005 has received FDA Orphan Drug and Fast Track designations and EMA orphan drug status for HIT. The release also notes the company’s broader pipeline includes tecarfarin, a late-stage oral vitamin K antagonist for chronic anticoagulation indications.